menu
    • menu
    [{"orgOrder":0,"company":"3M Company","sponsor":"IDRI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"3M-052","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"3M Company \/ IDRI","highestDevelopmentStatusID":"4","companyTruncated":"3M Company \/ IDRI"},{"orgOrder":0,"company":"3M Company","sponsor":"Baiya Phytopharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"25 Baiya SARS-CoV-2 Vax 2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"6","companyTruncated":"3M Company \/ 3M Company"}]

    Find Clinical Drug Pipeline Developments & Deals by 3M Company

    Menu

    3M Company

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            3M Company

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Baiya Phytopharm

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            3M Adjuvant Boosts Immune Response to Plant-Based COVID-19 Vaccine in Thailand Clinical Trials

                            Details : Baiya’s SARS-CoV-2 Vax 2 is second-generation plant-produced vaccine modelled on prototype SARS-CoV-2 RBD antigen adjuvanted with 3M-052-AF-alum. Data from first cohort of 12 participants demonstrated no significant changes in vital signs during first ...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 29, 2022

                            Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Baiya Phytopharm

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            3M Company

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3M-052,Potassium Alum

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : IDRI

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential

                            Details : Vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with IDRI’s novel formulation of 3M’s “3M-052” compound Produced more “broadly neutralizing antibodies” against several strains of coronavirus, including b...

                            Brand Name : 3M-052

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 03, 2021

                            Lead Product(s) : 3M-052,Potassium Alum

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : IDRI

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth